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Presently, in the majority of common diseases, 
therapeutic interventions are driven by the re‑
sults of randomized controlled clinical trials. How‑
ever, such an approach is almost impossible in 
diseases with very low prevalence. Yet, together, 
these rare diseases (less than 1/2000) pose a sub‑
stantial health problem. This issue has been recog‑
nized by the European Union, which, in 2009, es‑
tablished the European Union Committee of Ex‑
perts on Rare Diseases (EUCERD). The so called 
Rare Diseases Registries (RDRs) provide a ma‑
jor tool to gain more precise knowledge about 
the epidemiology of these diseases and to per‑
form therapeutic research. Recommendations 
to create such registries have been recently pub‑
lished by the EUCERD.1
Although it is commonly perceived that the ma‑
jority of rare diseases have a genetic background, 
many of them are acquired. Vasculitides belong 
to the latter group. Their prevalence is estimated 
at 1–9/100,000 and the annual incidence at about 
20 patients per million.2 Thus, in Poland, we can 
expect about 750 new cases every year. Vasculi‑
tides are a heterogeneous group of diseases with 
unknown etiology and the clinical spectrum rang‑
ing from life‑threatening systemic involvement to 
minor isolated skin changes. Nomenclature and 
definitions of systemic vasculitides have been re‑
cently updated by the International Chapel Hill 
Consensus Conference.3
With time, updates will be necessary as our 
knowledge continues to expand. Owing to the rar‑
ity of these syndromes, a specialist expertise is 
required to establish diagnosis and institute 
the most effective available treatment. This re‑
sulted in an international initiative to develop 
new diagnostic and classification criteria.4 Si‑
multaneously, there is an unmet need to identify 
the subsets of patients at risk for relapses, more 
severe course of the disease, grumbling disease, 
end‑stage organ failure, or infectious complica‑
tions. Recently, a study by Lyons et al.5 has point‑
ed to the genetic differences between 2 types of 
antineutrophil cytoplasmic antibody‑associated 
vasculitis (AAV), while the cluster analysis of 
a large cohort of AAV patients identified several 
clinically discrete subsets of AAV.6
To deal with these problems, large patient da‑
tabases in the form of RDRs are definitely re‑
quired. RDRs will also allow to identify specif‑
ic biomarkers and prognostic factors to classify 
and predict the future course of different types 
of vasculitides and, especially, effective treatment 
schemes. Such registries already exist in Europe 
(e.g., French Vasculitis Study Group) and United 
States (Vasculitis Clinical Research Consortium).
The 2nd Department of Internal Medicine of 
the Jagiellonian University Medical College in 
Kraków, Poland, has been involved in research 
and management of vasculitis for many years 
now. We participate in one of the clinical trials 
of the European Vasculitis Society (EUVAS) and 
American College of Rheumatology/European 
League against Rheumatism study of Diagnostic 
and Classification Criteria in Vasculitis (DCVAS). 
We also serve as an informal regional vasculi‑
tis reference center covering the population of 
over 3 million people. Our mission is to provide 
high‑quality clinical care together with scientif‑
ic contribution to the field of vasculitis research. 
For these reasons, we have established a local 
vasculitis study group, called the Krakow Vascu‑
litis Study Group (KRAKVAS). One of its major 
tasks is to set up a large vasculitis database for 
clinical and research purposes, which can also 
serve as the quality‑of‑care registry according to 
the European guidelines for RDRs. To this end, 
we have developed a web‑based electronic da‑
tabase for continuous data storage and analysis 
(FIGURE). The software enables prospective cen‑
tral collection of anonymized clinical data with 
the local storage of patient‑identifiable informa‑
tion. The project has been approved by the Jagi‑
ellonian University Ethics Committee. The regis‑
try, in which prevalent and incident cases of sys‑
temic vasculitides will be recruited, consist of 
2 parts: one with a core data set with basic demo‑
graphic and disease‑related variables and the oth‑
er with disease assessment scores (Birmingham 
Vasculitis Activity Score, Vasculitis Damage In‑
dex, and 36‑Item Short Form Health Survey), data 
on immunosuppressive treatment, comorbidities, 
and mortality in a longitudinal follow‑up section. 
Prospective data collection will be coupled with 
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dealing with vasculitides in their everyday prac‑
tice will gain access to a valuable source of pro‑
fessional information.
In summary, our center has developed the lo‑
cal online electronic vasculitis database for data 
storage and analysis, which may improve diagno‑
sis and treatment of various vasculitis syndromes. 
Its main future goal is to establish a platform for 
cooperation with other centers at the national 
level leading to the development of the national 
vasculitis registry.
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DNA, plasma, serum, urine, and tissue samples 
biobanking. Efforts have been undertaken to se‑
cure the safety of data and multilevel access to 
the registry.
We hope that this registry will be a starting 
point for establishing a country‑wide vasculitis 
registry in Poland through the cooperation with 
other national centers with experience in vascu‑
litis management. Data collected anywhere in 
the country will be entered using a web‑based 
application and stored in an anonymized format 
in the central database. Each participating cen‑
ter would have exclusive access to their data, and 
its common use for research purposes will be reg‑
ulated by the formal agreement signed by each 
participating center. Such examples of successful 
cooperation at the national level are the Czech 
Vasculitis Registry and UK and Ireland Vasculi‑
tis Registry (UKIVAS), which so far have enrolled 
over 500 patients with systemic vasculitis each. 
The variables that will be recorded should be com‑
patible with those existing datasets as this would 
allow to merge the collected data. There is an on‑
going effort to develop a large international vas‑
culitis registry and Poland should actively par‑
ticipate in this initiative. As already mentioned, 
such a large dataset will facilitate large‑scale epi‑
demiological, genetic, and therapeutic studies. It 
will also provide a means of linking data on unli‑
censed therapies, e.g., novel biologics.
In a long‑term perspective, we can envision 
coupling of the information about history and 
course of the disease with artificial neural net‑
work attempting to plan and optimize treatment 
as well as predict future outcome of patients with 
vasculitis syndromes.
In a few weeks, we will be launching a website 
on vasculitis both for patients and health care 
professionals (www.zapalenianaczyn.pl). Thus, 
both groups will get a possibility to directly con‑
tact medical consultants and to join patient sup‑
port groups, which may help them adjust to living 
with a chronic health problem. On the other hand, 
physicians and other health care professionals not 
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